The purpose of this study is to determine the performance of the Agili-C implants. The study hypothesis is that Agili-C implants are effective in the treatment of focal cartilage and cartilage-bone joint surface defects.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18 to 55 years
✓. Symptomatic, single, focal, full or near full-thickness (ICRS cartilage defect description grades 3 and 4) chondral or osteochondral isolated lesion of the femoral condyle, trochlea or the tibial plateau
✓. Primary or secondary articular cartilage repair.
✓. Knee is stable or can be stabilized as a concomitant procedure.
✓. Must be physically and mentally willing and able to comply with post-operative rehabilitation and routinely schedule clinical and radiographic visits.
✓. Signed informed consent.
✓. Any misalignments should be fully corrected at the end of the operative procedure.
Exclusion criteria
✕. Uncorrected axial misalignments \>5° that cannot be corrected.
✕. Patellar cartilage defects or pathology.
✕. Meniscal resection of more than 50%, either in a previous procedure or concomitant with articular cartilage repair.
✕. Any tumor of the ipsilateral knee, any concurrent malignant tumor or any metastatic tumor in the past or in the present.
✕. Active acute or chronic infection of the treated knee.
✕. Inflammatory arthropathy or crystal-deposition arthropathy.
✕. Systemic cartilage and/or bone disorder; This implants integration is dependent on surrounding live bleeding bone; therefore it must not be implanted within sequestrated or necrotic bone.